p38 Mitogen-Activated Protein Kinase: A Future Target for Heart Failure Therapy?
- 1 August 2006
- journal article
- editorial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 48 (3) , 556-558
- https://doi.org/10.1016/j.jacc.2006.05.005
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Activation of p38 Mitogen-Activated Protein Kinase Contributes to the Early Cardiodepressant Action of Tumor Necrosis FactorJournal of the American College of Cardiology, 2006
- Targeted Anticytokine Therapy and the Failing HeartThe American Journal of Cardiology, 2005
- Cytokine-Induced Modulation of Cardiac FunctionCirculation Research, 2004
- Tumor Necrosis Factor Receptors 1 and 2 Differentially Regulate Survival, Cardiac Dysfunction, and Remodeling in Transgenic Mice With Tumor Necrosis Factor-α–Induced CardiomyopathyCirculation, 2004
- Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac PhenotypesCirculation, 2004
- Inflammatory Mediators and the Failing HeartCirculation Research, 2002
- Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarctionProceedings of the National Academy of Sciences, 2000
- Activation of c-Jun N-Terminal Kinases and p38-Mitogen-activated Protein Kinases in Human Heart Failure Secondary to Ischaemic Heart DiseaseJournal of Molecular and Cellular Cardiology, 1999
- Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart FailureNew England Journal of Medicine, 1990
- Shock and Tissue Injury Induced by Recombinant Human CachectinScience, 1986